Tianjin Institute of Pharmaceutical Research Co., Ltd.

Qian Shang

Wei Liu

Yuquan Li

Lida Tang

Weiren Xu

Guilong Zhao

Yuli Wang

Yafei Xie

Bingni Liu

Yuqiang Liu

Jingwei Wu

Changying Liu

Haizhi Zhang

Xuyuan Liu

Huihui Chen

Yingmei Han

Guangping Xia

Naxia Zhao

Weiling Kong

Jing Jin

Xiaohua Kong

Zhixing Zhou

Chuan Li

Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: wherein the definitions of X, X, X, X, X, X, X, X, X, X, X, X, X, Xand Xare consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Glucagon-derived peptide and use thereof

The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, 

Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof

Growing community of inventors

Tianjin, China

Qian Shang